투석전 만성신부전 환자에서 Epoetin-α와 Darbepoetin-α의 2주 1회 요법의 조혈효과 비교 = Comparison of Once-Biweekly Administration of Epoetin-α with Darbepoetin-α in Chronic Kidney Disease Patients Not Receiving Dialysis

다국어 초록 (Multilingual Abstract)

Purpose: It is very important to correct renal anemia by erythropoiesis stimulating agents (ESA) be-cause anemia is associated with poor outcomes in chronic kidney disease (CKD) patients. We investigated whether once-biweekly (Q2W) treatment with epoetin- (EPO-) is as effective as Q2W darbe-poetin- (DA-α) in CKD patients who are not on dialysis. Methods: Fifteen CKD patients not receiving dialysis with renal anemia (M:F 6:9, age 60.1±7.2 years, eGFR-MDRD 15.7±6.4 mL/min/1.73m2, DM 46.7%) were enrolled. All patients received Q2W subcutaneous DA-α(40μg) for 10 weeks. After 6 weeks of wash-out period, patients were switched to Q2W subcutaneous EPO- (10,000 IU) for 10 weeks. Results: There were no significant differences in baseline parameters, such as hemoglobin (Hb), serum ferritin, and transferrin saturation, between before DA- therapy and before EPO-α therapy. Hb levels significantly increased after completion of ESA therapy (DA-α, 9.8±0.4 vs. 10.4±0.6 g/dL, p=0.001; EPO-α, 9.6±0.7 vs. 10.2±0.4 g/dL, p=0.003). After completion of ESA therapy, Hb levels did not reveal significant differences between two groups (p=0.123). Erythropoietin resistance index (8.2±1.6 vs. 8.4±1.5 IU/kg weight/g hemoglobin/week, p=0.136) and % increase of Hb (106.7±5.5 vs. 106.8±6.4%, p= 0.776) were not significantly different between DA-α therapy and EPO-α therapy. There were no signi-ficant adverse effects observed during study periods. Conclusion: These findings indicate that Q2W high dose (10,000 IU) of EPO-α therapy in CKD patients who are not on dialysis may be effective in maintaining Hb levels as Q2W DA-α therapy.

참고문헌 (Reference)

1 여호명, "지속성 외래 복막투석 환자에서 고용량 (10,000 IU) Epoetin Alfa (에스포젠(R))의 효과" 대한신장학회 24 (24): 441-447, 2005

2 Roger SD, "What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?" 9 : 223-228, 2004

3 Rosner MH, "The mortality risk associated with higher hemoglobin: is the therapy to blame?" 74 : 695-697, 2008

4 Hirai T, "Switching from epoetin alpha to darbepoetin alpha in Japanese hemodialysis patients: dose conversion ratio" 111 : C81-C86, 2009

5 Piccoli A, "Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia" 15 : 565-574, 2002

6 Pérez-García R, "Resistance index to epoetin alpha and to darbepoetin-alpha in chronic hemodialysis patients: a cohort study" 27 : 340-349, 2007

7 Al-Ahmad A, "Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction" 38 : 955-962, 2001

8 Nissenson AR, "Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients" 40 : 110-118, 2002

9 Vanrenterghem Y, "Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients" 62 : 2167-2175, 2002

10 Cervelli MJ, "Randomized cross-over comparison of intravenous and subcutaneous darbepoetin dosing efficiency in haemodialysis patients" 10 : 129-135, 2005

11 Perlman RL, "Quality of life in chronic kidney disease (CKD): a cross-sectional analysis in the Renal Research Institute-CKD study" 45 : 658-666, 2005

12 Goicoechea M, "Predictive cardiovascular risk factors in patients with chronic kidney disease (CKD)"

13 Macdougall IC, "Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients" 10 : 2392-2395, 1999

14 McGowan T, "Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis" 3 : 1006-1014, 2008

15 Provenzano R, "Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study" 64 : 113-123, 2005

16 Kanbay M, "Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: Review of causes and management" 29 : 1-12, 2010

17 Benz R, "Epoetin alfa once every 2 weeks is effective for initiation of treatment of anemia of chronic kidney disease" 2 : 215-221, 2007

18 Horowitz J, "Empirical methods to calculate an erythropoiesis-stimulating agent dose conversion ratio in nondialyzed patients with chronic kidney disease" 15 : 741-750, 2009

19 Bock HA, "Darbepoetin alpha in lower-than-equimolar doses maintains haemoglobin levels in stable haemodialysis patients converting from epoetin alpha/beta" 23 : 301-308, 2008

20 Jadoul M, "Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients" 19 : 898-903, 2004

21 Pussell BA, "Australian haemodialysis patients on intravenous epoetin alfa or intravenous darbepoetin alfa: How do they compare?" 12 : 126-129, 2007

22 Kazmi WH, "Anemia: an early complication of chronic renal insufficiency" 38 : 803-812, 2001

23 Mohanram A, "Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy" 66 : 1131-1138, 2004

24 Spinowitz B, "A randomized study of extended dosing regimens for initiation of epoetin alfa treatment for anemia of chronic kidney disease" 3 : 1015-1021, 2008

25 Pergola PE, "A randomized controlled study of weekly and biweekly dosing of epoetin alfa in CKD Patients with anemia" 4 : 1731-1740, 2009